Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HD11 for Intermediate Stage Hodgkin Lymphoma
NCT00264953Phase 3Completed
- Sponsor
- University of Cologne
- Start
- May 1998
- Primary completion
- Jan 2003
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Covalent Small Molecules
01
Overview
Phase 3, randomised, open-label trial of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine and 2 more in Hodgkin lymphoma (HL) (4 arms), sponsored by University of Cologne. Primary endpoint: Freedom from Treatment Failure at 5 years. Started May 1998; status: completed.
02
Drugs
bleomycinetoposidedoxorubicincyclophosphamidevincristine
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00264953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00264953.